Overall, NAT2-ATP7B risk genotypes were present in 13.9% of all AT-DILI patients (n = 72), which was significantly greater than the corresponding proportions in the treatment-tolerant controls (n = 205; 0.5%) and population controls (n = 1048; 1.8%, Supplementary Table 8). The gene discussed is NAT2; the disease is ataxia telangiectasia.